Business
Lightstone Ventures Marks Year-to-Date 2025 Milestones for its Innovative Biotech and Medtech Portfolio Companies
Lightstone Ventures today highlighted recent progress across its portfolio of innovative biotechnology and medical device companies, and further enhanced its leadership team.
About this update from Shoulder Innovations, Inc.
[{"type":"text","content":"Supported successful recent private financing rounds for portfolio companies totaling approximately $725 million year-to-date","length":125,"tagName":"p","attribs":{}},{"type":"text","content":"Helped oversee Shoulder Innovations $75 million IPO on NYSE","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"Enhanced strategic advisory and leadership capabilities","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"PORTOLA VALLEY, Calif. and BOSTON, Sept. 24, 2025 /PRNewswire/ -- Lightstone Ventures today highlighted recent progress across its portfolio of innovative biotechnology and medical device companies, and further enhanced its leadership team.","length":240,"tagName":"p"},{"type":"text","content":""The Lightstone team, together with our partners at the many innovative biotech and medtech companies that we are proud to support, have achieved meaningful milestones this year that we want to recognize," said Mike Carusi, Managing Partner at Lightstone Ventures. "So far in 2025, we have seen our portfolio companies close approximately $725 million in private financing rounds, alongside premier investors who share our vision of breakthrough therapies for patients in need across many therapeutic areas. We were also delighted to announce Shoulder Innovations' successful public listing on the NYSE, adding to the list of IPOs and M&A events for some of Lightstone's most impactful portfolio companies. Our focus remains on partnering with visionary founders to build impactful companies that transform novel ideas into commercially viable products."","length":886,"tagName":"p"},{"type":"text","content":"Key Financing Highlights Through September 2025 ","length":47,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FIRE1 – $120 million Series B round closed in January 2025","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Trotana Therapeutics – $52.5 million Series A round closed in February 2025","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Atsena Therapeutics – $150 million Series C round closed in April 2025","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Allay Therapeutics – $57.5 million Series D round closed in June 2025","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Shoulder Innovations ...